Showing 5321-5330 of 5771 results for "".
- Takeda CEO Optimistic About Growth Prospects as Drugmaker Finalizes Shire Takeoverhttps://modernod.com/news/takeda-ceo-optimistic-about-growth-prospects-as-drugmaker-finalizes-shire-takeover/2476205/Takeda announced that it has completed its $62-billion acquisition of Shire. Christophe Weber, chief executive of Takeda, stated “this marks a significant moment in [our] history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicin
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Riata Capital’s Acuity Eyecare Group Completes Acquisitions in Colorado and Nebraskahttps://modernod.com/news/riata-capitals-acuity-eyecare-group-completes-acquisitions-in-colorado-and-nebraska/2476208/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of leading North American eyecare groups and optometry practices, has acquired two new regional eyecare groups, totaling 18 locations: ABBA Eye Care, based in Colorado Springs, Colora
- Leica Biosystems Receives US Patent for RTF Extreme Speed Scanning Technologyhttps://modernod.com/news/leica-biosystems-receives-us-patent-for-rtf-extreme-speed-scanning-technology/2476211/Leica Biosystems announced that the US Patent Office has granted it a patent for RTF, its “Real-Time Focusing” technology (US patent 9,841,590). Leica says this will enable high volume, extremely fast line scanning of anatomic pathology slides. “RTF technology dramaticall
- RightEye Surpasses 100,000 Patient Testshttps://modernod.com/news/righteye-surpasses-100000-patient-tests/2476212/RightEye announced that more than 100,000 RightEye patient tests have been administered. In addition to RightEye’s growing popularity among optometrists, RightEye is becoming a standard for functional neurologists, sp
- Healthe Named One of the Nation’s 20 Hottest Health Start-Upshttps://modernod.com/news/healthe-named-one-of-the-nations-20-hottest-health-start-ups/2476213/Healthe, an eye health company that develops products and technology to block ultra-violet and high-energy visible blue light, announced that it was selected by THE OBSERVER as one of the nation’s hottest digital health companies. The list focuses on non-coastal, start-ups from the Midwest, South
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseaseshttps://modernod.com/news/exonate-closes-1-5-million-fundraising-accelerate-development-eye-drop-treatment-for-retinal-neovascular-diseases/2476222/Exonate announces the successful closing of its fourth financing round, raising £1.5 million. The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases. The company continues to make substantial progress an